Disc Medicine

Yahoo Finance • 14 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction... Full story

Yahoo Finance • 8 days ago

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from all... Full story

Yahoo Finance • 11 days ago

ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting fro... Full story

Yahoo Finance • last month

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment... Full story

Yahoo Finance • last month

Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection

Jean M. Franchi, Chief Financial Officer of Disc Medicine(NASDAQ:IRON), executed open-market sales of 11,156 shares for approximately $720,000 across three transactions on Feb. 17 and Feb. 18, 2026, as disclosed in a recent SEC Form 4 fili... Full story

Yahoo Finance • 2 months ago

Disc Medicine's Multiple Catalysts Provide Runway Despite Bitopertin Delay, Morgan Stanley Says

Disc Medicine (IRON) faces a delayed timeline for bitopertin after receiving a complete response let PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of the PPIX biomarker in protoporphyriaFDA... Full story

Yahoo Finance • 4 months ago

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor therapy use WATERTOWN, Mass., Dec. 06, 2025 (GLOB... Full story

Yahoo Finance • 6 months ago

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffe... Full story

Yahoo Finance • 6 months ago

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National Priority Voucher (CNPV), a program des... Full story

Yahoo Finance • 6 months ago

Sector Update: Health Care Stocks Higher Late Afternoon

Health care stocks rose late Friday afternoon with the NYSE Health Care Index climbing 0.2% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 6 months ago

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering fro... Full story

Yahoo Finance • 6 months ago

Achieve, Disc, Revolution among winners of initial FDA national priority vouchers

[US Food and Drug Administration (FDA)] Achieve Life Sciences (NASDAQ:ACHV [https://seekingalpha.com/symbol/ACHV]), Disc Medicine (NASDAQ:IRON [https://seekingalpha.com/symbol/IRON]), and Revolution Medicines (NASDAQ:RVMD [https://seeking... Full story

Yahoo Finance • 6 months ago

Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPPThe CNPV program is designed to reduce the drug application review process to 1-2 months WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) --... Full story

Yahoo Finance • 6 months ago

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)

Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc... Full story

Yahoo Finance • 8 months ago

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equival... Full story

Yahoo Finance • 8 months ago

Cantor Fitzgerald reiterates Overweight rating on Disc Medicine stock

Investing.com - Cantor Fitzgerald maintained its Overweight rating and $132.00 price target on Disc Medicine (NASDAQ:IRON) on Wednesday. The company, currently trading at $58.18 with a market capitalization of $2 billion, has seen its stoc... Full story

Yahoo Finance • 8 months ago

Bitterman Kevin, director at Disc Medicine, sells $1.96m in iron stock

Director Kevin Bitterman of Disc Medicine, Inc. (NASDAQ:IRON) sold a total of 32,174 shares of common stock on August 13 and 14, 2025. The sales, executed under a prearranged Rule 10b5-1 trading plan, totaled $1.96 million. The biotech com... Full story

Yahoo Finance • 9 months ago

Disc medicine CFO Franchi sells $119k in shares

Jean M. Franchi, Chief Financial Officer of Disc Medicine, Inc. (NASDAQ:IRON), sold 2,031 shares of common stock on July 17, 2025, at a price of $59.00, totaling $119,829. The transaction occurred near the stock’s current trading price of... Full story

Yahoo Finance • 9 months ago

Commodity Roundup: Gold rises as tariff worries lift safe-haven demand ahead of key inflation data

[gold bars on brown background] Sanlad/iStock via Getty Images Gold prices (XAUUSD:CUR [https://seekingalpha.com/symbol/XAUUSD:CUR]) edged higher on Tuesday as concerns over the impact of US tariffs boosted the metal’s safe-haven appeal,... Full story